Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT03037385 |
Title | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) |
Recruitment | Recruiting |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | Yes |
Sponsors | Blueprint Medicines Corporation |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | ITA | GBR | FRA | ESP | DEU | BEL |